The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
 
Ronan Joseph Kelly
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sanyo; Eisai; EMD Serono; Grail; Ipsen; Lilly; McKesson; Medscape; Merck; Novartis; Novocure; Onc Live; Peerview; Philips Healthcare; Pieris Pharmaceuticals; STERIS; Takeda; Toray Industries
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
Expert Testimony - Merck
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Jeeyun Lee
Consulting or Advisory Role - AstraZeneca; Guardant Health AMEA; Mirati Therapeutics; Oncologie; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme
 
Fumiyoshi Okano
Employment - Toray Industries
Leadership - Toray Industries
Stock and Other Ownership Interests - Toray Industries
Travel, Accommodations, Expenses - Toray Industries
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)